Compare MGYR & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGYR | PMN |
|---|---|---|
| Founded | 1922 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.3M | 136.2M |
| IPO Year | 2021 | 2022 |
| Metric | MGYR | PMN |
|---|---|---|
| Price | $17.49 | $13.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 3.2K | ★ 55.9K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ 26.83 | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.03 | $0.29 |
| 52 Week High | $20.00 | $27.40 |
| Indicator | MGYR | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.27 | 57.99 |
| Support Level | $16.80 | $12.80 |
| Resistance Level | $17.69 | $14.40 |
| Average True Range (ATR) | 0.23 | 1.31 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 59.21 | 38.34 |
Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.